Options flow is telling two distinct stories in tech right now. Bullish and bearish bets are piling into the same names — but with very different intentions.
NVDA tops both sides of the ledger. It leads the market for positive options bets over the past seven days. It also ranks third for negative bets. That two-way tension reflects genuine uncertainty. The stock is up just 6.4% year-to-date. Analysts still see 36% upside to target price. The next catalyst — Q1 2027 results — is months away.
TSLA and AMD appear on both lists too. Tesla is down 13% YTD. AMD has surged 68%. Both attract heavy put and call volume — classic battleground names where conviction runs in opposite directions.
Arvinas tells a cleaner story. The biotech just won FDA approval alongside PFE for a first-in-class breast cancer therapy. Options expiries are clustered at May 15 and June 18. Post-approval call activity is the focus. Pfizer has near-dated expiries every week through July — signalling persistent speculative interest.
GME is back in the spotlight. Ryan Cohen's proposed eBay deal is stoking call activity. The $20 strike for May 15 expiry drew 1,166 put contracts in a single session — suggesting some traders are fading the spike.
The broader signal: bulls are concentrated in AI and semiconductor names. Bears are hedging the same sector. This standoff often precedes a sharp move in one direction.
This is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
